Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment
| Autor: | Hiroaki Matsuura, Ken Sato, Yoko Shinno, Daisuke Minami, Atsushi Shimonishi, Keiichi Fujiwara, Sachi Okawa, Taichi Ozeki, Kosuke Ota, Takuo Shibayama, Hiroe Kayatani, Jun Nishimura |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Case Report Gastroenterology lcsh:RC254-282 immune checkpoint inhibitors 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine renal biopsy Internal medicine Medicine Adverse effect Acute tubular necrosis nivolumab Creatinine medicine.diagnostic_test business.industry Acute kidney injury medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030104 developmental biology Oncology chemistry acute kidney injury acute tubular necrosis 030220 oncology & carcinogenesis Prednisolone Renal biopsy Nivolumab business CD163 medicine.drug |
| Zdroj: | Case Reports in Oncology, Vol 13, Iss 1, Pp 85-90 (2020) Case Reports in Oncology |
| ISSN: | 1662-6575 |
| Popis: | A 63-year-old man with pulmonary adenocarcinoma was treated with nivolumab. High fever developed within several hours after the first administration of nivolumab; subsequently, serum creatinine levels kept increasing daily. We diagnosed acute kidney injury (AKI) as an immune-related adverse event; the patient was initially treated with 50 mg prednisolone, and the dose was then tapered. Renal biopsy pathologically revealed tubulointerstitial inflammation with strong infiltration of only T cells that were CD3+, CD4+, and CD8+. The infiltration of CD163+ M2 macrophage was also observed. AKI within 1 week after the administration of nivolumab seems to be rare; therefore, the present case provides important findings useful in daily clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |